[The results of treating fibrous-cavernous tuberculosis in patients with different genetic markers].
Overall 221 patients with fibrous-cavernous tuberculosis were examined. In patients carrying Hp 2-2 haptoglobin and HLA DR2, the disease runs an unfavourable course more frequently. Among the patients with Hp 2-2, the positive dynamics was attained by the 6th month of the treatment in 44.1%, among those with HLA DR2 in 42.3% of cases while in patients carrying the two genetic markers at a time, in only 32.4% of cases. Patients with Hp 2-2 and HLA DR2 require special attention of the treating physician since the very first day of the disease and use of every possible treatment methods.
Khomenko
A G
AG
Sadykov
A S
AS
D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006684:HLA-DR Antigens / Q000235:genetics; D006242:Haptoglobins / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000235:genetics
D000995:Antitubercular Agents; D005819:Genetic Markers; D006684:HLA-DR Antigens; D006242:Haptoglobins
Rezul'taty lecheniia fibrozno-kavernoznogo tuberkuleza u bol'nykh s razlichnymi geneticheskimi markerami.